Siga Technologies, Inc. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of novel medical countermeasures to address orthopoxvirus infections such as smallpox and mpox. Headquartered in Maryland, the company combines proprietary antiviral research with government-sponsored programs to deliver therapeutics designed for rapid response to biological threats. Since its formation in 2012, Siga has positioned itself as a key supplier of approved antiviral therapies while continuing to expand its pipeline of next-generation treatments.
The company’s flagship product is TPOXX (tecovirimat), the first FDA-approved antiviral for smallpox. TPOXX is manufactured under stringent cGMP conditions and is held in the U.S. Strategic National Stockpile through contracts with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense. In addition to smallpox, Siga is advancing research into related orthopoxviruses and exploring broad-spectrum antiviral candidates to address emerging viral threats.
Siga serves a global customer base that includes U.S. federal agencies, international health organizations and allied government partners. The company has established supply agreements with the European Commission and is engaged with public health authorities in Canada, Australia and select NATO members. Siga’s operations encompass research laboratories in New York, strategic manufacturing partnerships in North America and Europe, and a regulatory team dedicated to securing approvals in key jurisdictions.
Under the leadership of Chairman and Chief Executive Officer Philip Gomez, Siga’s senior management team brings extensive experience in pharmaceutical development, government contracting and commercial operations. Chief Financial Officer John Dahl oversees corporate strategy and finance, while the board of directors features former public health officials and biodefense experts. Together, they guide Siga’s mission to strengthen global preparedness through innovative antiviral solutions.
AI Generated. May Contain Errors.
